A retrospective study of nivolumab or pembrolizumab in patients with metastatic melanoma who previously experienced severe ipilimumab immune-related adverse events
Latest Information Update: 24 Jul 2020
At a glance
- Drugs Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Brain metastases; Malignant melanoma
- Focus Adverse reactions
- 15 Jul 2020 Results evaluating the risk of a recurrence of immune toxic effects associated with anti-programmed cell death 1 antibody (anti-PD-1) therapy after discontinuation of ipilimumab monotherapy because of severe AEs, published in the JAMA Dermatology.
- 29 Jul 2016 New trial record
- 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology